The varicella-zoster virus that causes shingles and chicken pox is typically present in over 90% of adults globally.

GSK has announced positive results from its first efficacy trial for Shingrix recombinant zoster vaccine (RZV) in China.

The results follow a post-license phase 4 trial (ZOSTER-076) from GSK, which evaluated the vaccine’s efficacy in preventing shingles in 6,000 individuals over the age of 50.

Those who received the Shingrix vaccination reported no cases, whereas the ones who were given the placebo reported 31 cases.

GSK also carried out the phase 3 trials ZOE-50 and ZOE-70, which demonstrated how the RZV vaccine’s efficacy was up to 97% over the length of four years.

RZV was originally used in 2019 for the prevention of herpes zoster in patients aged over 50, and trials were consequently put in place for the treatment of shingles after its success – the current trials further demonstrate the vaccine’s efficacy for preventing herpes, regardless of sex, ethnicity or geographical region.

The varicella-zoster virus (VZV) that causes shingles and chicken pox is typically present in over 90% of adults globally; it remains in the nervous system until it attempts to reactivate as shingles as age increases.

As the population in China increases, the six million cases of shingles annually are also expected to increase, making this a rising issue for people over the age of 65.

The results from the phase 4 trial will be published later this year in a peer-reviewed scientific journal, GSK said.